Question

A 27-year-old Latino male presents to your office to inquire about quitting smoking. He has tried NicoDerm in the past with no success. He states that a few of his friends are “vaping” and wonders if this would be a good option for him. Would you recommend this? If not, what would you recommend? Include medication pharmacotherapeutics, pharmacodynamics, pharmacokinetics, patient monitoring, and education.

Answer 1

No vaping is not a good option for him to quit smoking.

Whether you’re taking combusted smoke into your lungs or vapor, there are going to be some quite serious health implications that come along with it. The health implications of smoking are a lot more defined and outlined then with vaping in the long term.

The main process of vaping removes the need to combust anything, removing a handful of the harmless chemicals.

Here are just a few of the chemicals found in vapor:-

-- Nicotine

-- Nitrosamines

-- Acetaldehyde

-- Propylene Glycol

Compared to smoking , the studies suggest that vaping has a significantly lower level of health risks. However, it has still seen its problems. E-cigarettes have had problems with their batteries exploding, which can cause extreme health and safety concerns.

Quit Smoking with the help of Doctor by sharing the problem properly like how many cigarettes they smoke a day, they smoke regularly or sometimes like all this things.

Pharmatherapeutics:- Special consideration should be given before using pharmacotherapy with selected populations: those with medical contraindications, those smoking less than 10 cigarettes/day, pregnant, and adolescent smokers.

Five of the FDA-approved pharmacotherapies for smoking cessation are recommended including bupropion SR, nicotine gum, nicotine inhaler, nicotine nasal spray, and the nicotine patch

Second line Pharmatherapeutics:-Clonidine and nortriptyline

Pharmatherapeutics used with patients concerned with weight gain:-Bupropion SR and nicotine replacement therapies in nicotine gum , have been shown to delay, but not prevent, weight gain

Pharmatherapeutics considered with patients of depression:- Bupropion SR and Nortriptyline

Pharmacodynamics:- Pharmacodynamic considerations are discussed in relation to the elements of smoking cessation therapy: setting objectives, selecting appropriate medication and dosing form, selecting the optimal doses and dosage regimens, assessing therapeutic outcome, and adjusting therapy to optimize benefits and minimize risks.

Varenicline tartrate (Chantix®/Champix®) is a selective partial agonist of the ?4?2 nicotinic acetylcholine receptor and is approved as an aid to smoking cessation.Varenicline is almost exclusively excreted unchanged in urine, primarily through glomerular filtration, with some component of active tubular secretion via human organic cation transporter, hOCT-2.

Pharmacokinetics:- Smoking is a complex behaviour involving both pharmacological and psychological components. Nicotine is the main alkaloid found in tobacco, and is responsible for its addictive potential. Nicotine-positive effects on mood and cognition are strong reinforcements for smokers that contribute to their addiction, and cigarette smoking is particularly addictive because inhaled nicotine is absorbed through the pulmonary venous rather than the systemic venous system, and thus reaches the brain in 10-20 seconds.

Education for quit smoking:- Three out of four smokers say they want to quit smoking and seven out of ten smokers have tired to quit smoking.

There will be withdrawal symptoms after quitting. Give

examples such as lack of concentration, feeling tired, or bein

restless.

The withdrawal symptoms may come and go, get stronger 0

weaker, or remain the same. Tell the smoker to be prepared

for these changes.

The withdrawal symptoms should last 2 to 4 weeks.

A person should be mentally strong and ready to quit smoking.